Milestone, a cardiovascular nasal spray developer that raised more than $167m in VC funding from investors including Novo, secured $82.5m in when it went public.

Milestone Pharmaceuticals, a Canada-based cardiovascular therapy developer backed by pharmaceutical firm Novo, raised $82.5m in its initial public offering yesterday after pricing its shares at $15.00 each. The company issued 5.5 million shares on the Nasdaq Global Select Market, in the middle of the IPO’s $14 to $16 range, valuing it at $354m. Its shares…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.